

# Gilberto Schwartsmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6152129/publications.pdf>

Version: 2024-02-01

237  
papers

7,924  
citations

70961

41  
h-index

69108

77  
g-index

249  
all docs

249  
docs citations

249  
times ranked

10452  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 195, 113861.	1.4	6
2	Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience. <i>Oncologist</i> , 2021, 26, e1581-e1588.	1.9	10
3	Resistance to differentiation affects ribo- and deoxyribonucleotide pools and sensitivity to pyrimidine metabolism antagonists in HL60 cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 1369-1378.	0.4	1
4	A quick UPLC-MS/MS method for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in human plasma. <i>Biomedical Chromatography</i> , 2020, 34, e4947.	0.8	3
5	Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer. <i>Ecancermedalscience</i> , 2020, 14, 1007.	0.6	33
6	Outcomes and prognostic factors of patients (pts) with metastatic colorectal cancer (mCRC) who underwent pulmonary metastasectomy (PM) with curative intent.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4034-4034.	0.8	0
7	Clinicopathological features and outcomes of patients with esophageal cancer undergoing neoadjuvant chemoradiation (chemoRT) in Southern Brazil: A comparison to the Worldwide Esophageal Cancer Collaboration.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16535-e16535.	0.8	0
8	KIR gene haplotype A is associated with hospital mortality in patients with sepsis. <i>Clinical Immunology</i> , 2019, 200, 37-38.	1.4	1
9	Tropomyosin-Related Kinase Receptor and Neurotrophin Expression in Cutaneous Melanoma Is Associated with a Poor Prognosis and Decreased Survival. <i>Oncology</i> , 2019, 97, 26-37.	0.9	18
10	Differences in Breast Cancer Stage at Diagnosis by Ethnicity, Insurance Status, and Family Income in Young Women in the USA. <i>Journal of Racial and Ethnic Health Disparities</i> , 2019, 6, 909-916.	1.8	24
11	Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells. <i>Journal of Molecular Neuroscience</i> , 2019, 68, 49-57.	1.1	11
12	Determination of Endogenous Concentrations of Uracil and Dihydrouracil in Dried Saliva Spots by LC-MS/MS: Method Development, Validation, and Clinical Application. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 383-390.	1.0	10
13	Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity. <i>Current Medicinal Chemistry</i> , 2019, 26, 2085-2107.	1.2	31
14	Treatment delay and outcomes in stage IV lung cancer: The reality of a public hospital in a developing country.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20709-e20709.	0.8	1
15	DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity. <i>Clinical Biochemistry</i> , 2018, 56, 18-25.	0.8	17
16	Epidermal Growth Factor Receptor Regulation of Ewing Sarcoma Cell Function. <i>Oncology</i> , 2018, 94, 383-393.	0.9	8
17	Analytical and clinical validation of a dried blood spot assay for the determination of paclitaxel using high-performance liquid chromatography-tandem mass spectrometry. <i>Clinical Biochemistry</i> , 2018, 54, 123-130.	0.8	16
18	Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 150, 51-58.	1.4	21

#	ARTICLE	IF	CITATIONS
19	Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. <i>European Journal of Cancer</i> , 2018, 105, 71-78.	1.3	24
20	Predicting 5-Fluorouracil related severe toxicity with DPD functional tests in plasma, fresh saliva and dried saliva samples.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14563-e14563.	0.8	0
21	Gastrin-Releasing Peptide Receptor Knockdown Induces Senescence in Glioblastoma Cells. <i>Molecular Neurobiology</i> , 2017, 54, 888-894.	1.9	10
22	KIR genes and HLA class I ligands in a Caucasian Brazilian population with colorectal cancer. <i>Human Immunology</i> , 2017, 78, 263-268.	1.2	11
23	Reduced frequency of two activating KIR genes in patients with sepsis. <i>Human Immunology</i> , 2017, 78, 363-369.	1.2	4
24	A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism. <i>Clinical Neuropharmacology</i> , 2017, 40, 108-112.	0.2	4
25	The anticancer estrogen receptor antagonist tamoxifen impairs consolidation of inhibitory avoidance memory through estrogen receptor alpha. <i>Journal of Neural Transmission</i> , 2017, 124, 1331-1339.	1.4	20
26	CXCR2 +1208 CT genotype may predict earlier clinical stage at diagnosis in patients with prostate cancer. <i>Cytokine</i> , 2017, 97, 193-200.	1.4	10
27	Targeting tyrosine receptor kinase B in gliomas. <i>Neuro-Oncology</i> , 2017, 19, 138-139.	0.6	18
28	Administration of a Histone Deacetylase Inhibitor into the Basolateral Amygdala Enhances Memory Consolidation, Delays Extinction, and Increases Hippocampal BDNF Levels. <i>Frontiers in Pharmacology</i> , 2017, 8, 415.	1.6	13
29	Efficacy and safety of liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 303-303.	0.8	0
30	Outcomes after the diagnosis of brain metastases in Brazilian NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20568-e20568.	0.8	0
31	An easy-to-handle DPD deficiency test in saliva to identify patients at high-risk for life-threatening toxicity due to fluoropyrimidine therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14019-e14019.	0.8	0
32	Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. <i>Clinical Biochemistry</i> , 2016, 49, 1221-1226.	0.8	22
33	Improvement in Symptoms of Autism Spectrum Disorder in Children With the Use of Gastrin-Releasing Peptide: An Open Trial. <i>Clinical Neuropharmacology</i> , 2016, 39, 215-219.	0.2	3
34	Histone deacetylase inhibition prevents the impairing effects of hippocampal gastrin-releasing peptide receptor antagonism on memory consolidation and extinction. <i>Behavioural Brain Research</i> , 2016, 307, 46-53.	1.2	8
35	Improvement of autism spectrum disorder symptoms in three children by using gastrin-releasing peptide. <i>Jornal De Pediatria</i> , 2016, 92, 302-306.	0.9	3
36	Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists. <i>Child's Nervous System</i> , 2016, 32, 61-64.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 545-557.	6.3	878
38	Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI), Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 417-417.	0.8	6
39	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI), Tj ETQq1 1 0.784314 rgBT /O cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4126-4126.	0.8	0
40	Outcomes of chemoradiotherapy neoadjuvant for esophagus cancer in Brazil.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15568-e15568.	0.8	0
41	Outcomes of chemoradiotherapy for stage III non-small-cell lung cancer in Brazil.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20073-e20073.	0.8	0
42	Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 733-744.	1.0	21
43	RC-3095, a Selective Gastrin-Releasing Peptide Receptor Antagonist, Does Not Protect the Lungs in an Experimental Model of Lung Ischemia-Reperfusion Injury. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	4
44	Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase. <i>Clinical Biochemistry</i> , 2015, 48, 915-918.	0.8	11
45	<i>CYP3A4*22</i> is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. <i>Pharmacogenomics</i> , 2015, 16, 601-617.	0.6	24
46	Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N -desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots&quot;Development, validation and clinical application during breast cancer adjuvant therapy. <i>Talanta</i> , 2015, 132, 775-784.	2.9	50
47	Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 234-234.	0.8	16
48	International Scientific Collaboration in HIV and HPV: A Network Analysis. <i>PLoS ONE</i> , 2014, 9, e93376.	1.1	46
49	A phosphodiesterase 4-controlled switch between memory extinction and strengthening in the hippocampus. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 91.	1.0	14
50	Gastrin-Releasing Peptide Receptor Expression in Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 98-104.	1.2	48
51	Expression of Gastrin-releasing Peptide Receptor in Epidermoid Carcinoma of the Anal Canal. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 459-463.	0.6	1
52	<sc>DEFB</sc> 1 gene 5â€² untranslated region (UTR) polymorphisms are marginally involved in inflammatory bowel disease in south <sc>B</sc>razilians. <i>International Journal of Immunogenetics</i> , 2014, 41, 138-142.	0.8	3
53	Inhibitory Activities of Trichostatin A in U87 Glioblastoma Cells and Tumorsphere-Derived Cells. <i>Journal of Molecular Neuroscience</i> , 2014, 54, 27-40.	1.1	14
54	Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients. <i>Clinical Biochemistry</i> , 2014, 47, 1084-1090.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Gastrin-releasing peptide receptor signaling in the integration of stress and memory. <i>Neurobiology of Learning and Memory</i> , 2014, 112, 44-52.	1.0	30
56	PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. <i>Investigational New Drugs</i> , 2014, 32, 783-794.	1.2	55
57	Long-term behavioral effects of neonatal blockade of gastrin-releasing peptide receptors in rats: Similarities to autism spectrum disorders. <i>Behavioural Brain Research</i> , 2014, 263, 60-69.	1.2	21
58	Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group. <i>Human Immunology</i> , 2013, 74, 1130-1133.	1.2	33
59	Failure of anti-EGFR therapy in p16-positive head and neck cancer. <i>Lancet Oncology</i> , The, 2013, 14, e436-e437.	5.1	2
60	Planning cancer control in Latin America and the Caribbean. <i>Lancet Oncology</i> , The, 2013, 14, 391-436.	5.1	394
61	Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells. <i>Child's Nervous System</i> , 2013, 29, 2145-2150.	0.6	8
62	Expression of gastrin-releasing peptide receptor in patients with cutaneous malignant melanoma. <i>Clinical and Experimental Dermatology</i> , 2013, 38, n/a-n/a.	0.6	5
63	The Histone Deacetylase Inhibitor Sodium Butyrate Promotes Cell Death and Differentiation and Reduces Neurosphere Formation in Human Medulloblastoma Cells. <i>Molecular Neurobiology</i> , 2013, 48, 533-543.	1.9	48
64	Antiproliferative activity of the dimeric phloroglucinol and benzophenone derivatives of <i>Hypericum</i> spp. native to southern Brazil. <i>Anti-Cancer Drugs</i> , 2013, 24, 699-703.	0.7	13
65	Influence of GRPR and BDNF/TrkB signaling on the viability of breast and gynecologic cancer cells. <i>Molecular and Clinical Oncology</i> , 2013, 1, 148-152.	0.4	13
66	GRPR antagonists for prostate cancer—prospects and caveats. <i>Nature Reviews Urology</i> , 2013, 10, 424-424.	1.9	1
67	Evolution of Truth-Telling Practices in Brazil and South America. , 2013, , 419-428.		1
68	Gastrin-Releasing Peptide as a Molecular Target for Inflammatory Diseases: An Update. <i>Inflammation and Allergy: Drug Targets</i> , 2013, 12, 172-177.	1.8	26
69	Gastrin-releasing peptide receptors in the central nervous system: role in brain function and as a drug target. <i>Frontiers in Endocrinology</i> , 2012, 3, 159.	1.5	49
70	Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 547-552.	3.3	61
71	Bombesin receptor regulation of emotional memory. <i>Reviews in the Neurosciences</i> , 2012, 23, 571-86.	1.4	25
72	The Gastrin-Releasing Peptide Receptor as a Marker of Dysplastic Alterations in Cervical Epithelial Cells. <i>Oncology</i> , 2012, 82, 90-97.	0.9	7

#	ARTICLE	IF	CITATIONS
73	BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. <i>Biochemical and Biophysical Research Communications</i> , 2012, 425, 328-332.	1.0	41
74	Glioma Revisited: From Neurogenesis and Cancer Stem Cells to the Epigenetic Regulation of the Niche. <i>Journal of Oncology</i> , 2012, 2012, 1-20.	0.6	40
75	Gastrin-Releasing Peptide Receptor Antagonism Induces Protection from Lethal Sepsis: Involvement of Toll-like Receptor 4 Signaling. <i>Molecular Medicine</i> , 2012, 18, 1209-1219.	1.9	12
76	Lung Cancer in Brazil. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 426-431.	1.8	0
77	Lymph Node Retrieval after Preoperative Chemoradiotherapy for Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1573-1580.	0.9	55
78	Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group. <i>International Journal of Immunogenetics</i> , 2012, 39, 423-428.	0.8	11
79	Rescue of social behavior impairment by clozapine and alterations in the expression of neuronal receptors in a rat model of neurodevelopmental impairment induced by GRPR blockade. <i>Journal of Neural Transmission</i> , 2012, 119, 319-327.	1.4	8
80	RNA expression of the molecular signature genes for metastasis in colorectal cancer. <i>Oncology Reports</i> , 2011, 25, 1321-7.	1.2	4
81	Gastrin-Releasing Peptide Receptor Antagonist or N-acetylcysteine combined with Omeprazol Protect against Mitochondrial Complex II Inhibition in a Rat Model of Gastritis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 214-219.	1.2	7
82	The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells. <i>Child's Nervous System</i> , 2011, 27, 897-901.	0.6	18
83	Regulation of E-cadherin expression by growth factor receptors in cancer cells. <i>Journal of Surgical Oncology</i> , 2011, 104, 220-221.	0.8	3
84	Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. <i>International Journal of Cancer</i> , 2011, 129, 671-679.	2.3	20
85	Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2956-2965.	6.7	30
86	BDNF/TrkB signaling as an anti-tumor target. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1473-1475.	1.1	32
87	Protective effect of gastrin-releasing peptide receptor antagonist in carrageenan-induced pleural inflammation in rats. <i>Inflammation Research</i> , 2010, 59, 783-789.	1.6	12
88	Effects of a gastrin-releasing peptide receptor antagonist on d-amphetamine-induced oxidative stress in the rat brain. <i>Journal of Neural Transmission</i> , 2010, 117, 309-316.	1.4	7
89	BDNF and PDE4, but not the GRPR, Regulate Viability of Human Medulloblastoma Cells. <i>Journal of Molecular Neuroscience</i> , 2010, 40, 303-310.	1.1	34
90	Effects of N-Acetylcysteine/Deferoxamine, Taurine and RC-3095 on Respiratory Chain Complexes and Creatine Kinase Activities in Rat Brain After Sepsis. <i>Neurochemical Research</i> , 2010, 35, 515-521.	1.6	25

#	ARTICLE	IF	CITATIONS
91	Effects of the Gastrin-Releasing Peptide Antagonist RC-3095 in a Rat Model of Ulcerative Colitis. Digestive Diseases and Sciences, 2010, 55, 2203-2210.	1.1	9
92	Mangiferin, a naturally occurring glucoxilxanthone improves long-term object recognition memory in rats. European Journal of Pharmacology, 2010, 635, 124-128.	1.7	54
93	Breast cancer in Latin America: Experts perceptions compared with medical care standards. Breast, 2010, 19, 50-54.	0.9	15
94	Histone deacetylase inhibitors: A new perspective for the treatment of leukemia. Leukemia Research, 2010, 34, 687-695.	0.4	26
95	The Effects of Sample Size on the Outcome of Ovarian Tissue Cryopreservation. Reproduction in Domestic Animals, 2010, 45, 99-102.	0.6	27
96	Current and emerging molecular targets in glioma. Expert Review of Anticancer Therapy, 2010, 10, 1735-1751.	1.1	31
97	Musical hallucinations following insular glioma resection. Neurosurgical Focus, 2010, 28, E9.	1.0	20
98	Influence of Purple Grape Juice in Cyclosporine Bioavailability. , 2010, 20, 309-313.		10
99	BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer. Oncology, 2010, 79, 430-439.	0.9	50
100	Study of killer immunoglobulin-like receptor genes and human leukocyte antigens class I ligands in a Caucasian Brazilian population with Crohn's disease and ulcerative colitis. Human Immunology, 2010, 71, 293-297.	1.2	22
101	Association of killer cell immunoglobulin-like receptors and human leukocyte antigen C genotypes in South Brazilian with type 1 diabetes. Human Immunology, 2010, 71, 799-803.	1.2	20
102	Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Research Bulletin, 2010, 82, 95-98.	1.4	34
103	Neonatal gastrin-releasing peptide receptor blockade reduces maternal odor preference in rats. Behavioural Brain Research, 2010, 214, 456-459.	1.2	10
104	HER2 as a cancer stem-cell target. Lancet Oncology, The, 2010, 11, 225-226.	5.1	17
105	The rare association of leukoencephalopathy, cerebral calcifications, and cysts: case report. Journal of Epilepsy and Clinical Neurophysiology, 2010, 16, 115-117.	0.1	0
106	Effects of an Antagonist of the Gastrin-Releasing Peptide Receptor in an Animal Model of Uveitis. , 2009, 50, 5300.		11
107	Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer. Brazilian Journal of Medical and Biological Research, 2009, 42, 979-987.	0.7	8
108	LETTER TO THE EDITOR. Neuro-Oncology, 2009, 11, 236-237.	0.6	0



#	ARTICLE	IF	CITATIONS
109	Cancer Stem Cells and the Biology of Brain Tumors. <i>Current Stem Cell Research and Therapy</i> , 2009, 4, 306-313.	0.6	19
110	Phosphodiesterase-4 Inhibition and Brain Tumor Growth. <i>Clinical Cancer Research</i> , 2009, 15, 3238-3238.	3.2	3
111	Systemic administration of doxorubicin impairs aversively motivated memory in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 94, 239-243.	1.3	47
112	A gastrin-releasing peptide receptor antagonist stimulates Neuro2a neuroblastoma cell growth: Prevention by a histone deacetylase inhibitor. <i>Cell Biology International</i> , 2009, 33, 899-903.	1.4	13
113	Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. <i>Journal of Neuro-Oncology</i> , 2009, 93, 191-201.	1.4	34
114	Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. <i>Leukemia Research</i> , 2009, 33, 218-221.	0.4	24
115	Phosphoinositide 3-kinase is required for bombesin-induced enhancement of fear memory consolidation in the hippocampus. <i>Peptides</i> , 2009, 30, 1192-1196.	1.2	19
116	Effect of a gastrin-releasing peptide receptor antagonist and a proton pump inhibitor association in an animal model of gastritis. <i>Peptides</i> , 2009, 30, 1460-1465.	1.2	10
117	Gastrin-releasing Peptide Receptor: A Potential Target in Treatment of IBD?. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 288.	1.1	1
118	Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist. <i>Protein and Peptide Letters</i> , 2009, 16, 650-652.	0.4	8
119	Emerging Therapeutic Agents for Cervical Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2009, 4, 196-206.	0.8	12
120	Synergistic effect of three benzopyrans isolated from <i>Hypericum polyanthemum</i> in U873 MG glioblastoma cell line. <i>Phytotherapy Research</i> , 2008, 22, 1577-1580.	2.8	9
121	Breast cancer in Latin America. <i>Cancer</i> , 2008, 113, 2359-2365.	2.0	36
122	A study of the killer cell immunoglobulin-like receptor gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris. <i>Tissue Antigens</i> , 2008, 72, 392-396.	1.0	25
123	Effects of an antagonist of the bombesin/gastrin-releasing peptide receptor on complete Freund's adjuvant-induced arthritis in rats. <i>Peptides</i> , 2008, 29, 1726-1731.	1.2	20
124	Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. <i>World Neurosurgery</i> , 2008, 70, 259-266.	1.3	113
125	Transient Disruption of Fear-Related Memory by Post-Retrieval Inactivation of Gastrin-Releasing Peptide or N-Methyl-D-Aspartate Receptors in the Hippocampus. <i>Current Neurovascular Research</i> , 2008, 5, 21-27.	0.4	14
126	Stimulation of Proliferation of U138-MG Glioblastoma Cells by Gastrin-Releasing Peptide in Combination with Agents That Enhance cAMP Signaling. <i>Oncology</i> , 2008, 75, 27-31.	0.9	33



#	ARTICLE	IF	CITATIONS
127	A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. <i>Annals of Oncology</i> , 2008, 19, 1547-1552.	0.6	167
128	Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism. <i>Current Neurovascular Research</i> , 2008, 5, 99-105.	0.4	30
129	Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. <i>Annals of Oncology</i> , 2007, 18, 1457-1466.	0.6	187
130	The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders. <i>Recent Patents on CNS Drug Discovery</i> , 2007, 2, 125-9.	0.9	6
131	Targeting the Epidermal Growth Factor Receptor in Colorectal Cancer: A Potential Therapeutic Role for Gastrin-Releasing Peptide Receptor Antagonists. <i>Oncology</i> , 2007, 72, 160-161.	0.9	2
132	Gastrin-Releasing Peptide Receptor Expression in Cervical Cancer. <i>Oncology</i> , 2007, 73, 340-345.	0.9	23
133	Gastrin-Releasing Peptide Receptor as a Molecular Target for Inflammatory Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2007, 6, 197-200.	1.8	22
134	Targeting the Bombesin/Gastrin-Releasing Peptide Receptor to Treat Sepsis. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2007, 2, 178-181.	0.5	5
135	A gastrin-releasing peptide receptor antagonist blocks d-amphetamine-induced hyperlocomotion and increases hippocampal NGF and BDNF levels in rats. <i>Peptides</i> , 2007, 28, 1447-1452.	1.2	18
136	Impairments of social behavior and memory after neonatal gastrin-releasing peptide receptor blockade in rats: Implications for an animal model of neurodevelopmental disorders. <i>Neuropharmacology</i> , 2007, 52, 724-732.	2.0	32
137	Evidence for an association of human papillomavirus infection and colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2007, 33, 569-574.	0.5	101
138	Bombesin protection against FK506 neurotoxicity. <i>Journal of Pediatric Surgery</i> , 2007, 42, 750.	0.8	3
139	When drugs are worth more than gold!. <i>Lancet Oncology</i> , The, 2007, 8, 1049-1050.	5.1	3
140	Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2007, 58, 80-87.	0.9	11
141	Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease. <i>Dementia E Neuropsychologia</i> , 2007, 1, 118-123.	0.3	3
142	Tumor Size as a Surrogate End Point for the Detection of Early Breast Cancer: A 30-Year (1972-2002), Single-Center Experience in Southern Brazil. <i>Breast Journal</i> , 2007, 13, 448-456.	0.4	13
143	The egos and the goals of reporting results. <i>Oral Diseases</i> , 2007, 13, 251-251.	1.5	0
144	Evaluation of antioxidant effect of extracts of <i>Symphiopappus casarettoi</i> . <i>Fã-toterapã-Ãç</i> , 2007, 78, 232-234.	1.1	3

#	ARTICLE	IF	CITATIONS
145	Basic Fibroblast Growth Factor Prevents the Memory Impairment Induced by Gastrin-Releasing Peptide Receptor Antagonism in Area CA1 of the Rat Hippocampus. <i>Neurochemical Research</i> , 2007, 32, 1381-1386.	1.6	8
146	Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. <i>International Journal of Colorectal Disease</i> , 2007, 22, 1201-1208.	1.0	34
147	Systemic treatment of AIDS-related Kaposi sarcoma: Current status and perspectives. <i>Cancer Treatment Reviews</i> , 2006, 32, 445-455.	3.4	52
148	Sentinel lymph node in carcinoma of the anal canal: A review. <i>European Journal of Surgical Oncology</i> , 2006, 32, 247-252.	0.5	51
149	Opposite effects of low and high doses of the gastrin-releasing peptide receptor antagonist RC-3095 on memory consolidation in the hippocampus: Possible involvement of the GABAergic system. <i>Peptides</i> , 2006, 27, 2307-2312.	1.2	33
150	Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. <i>Neuropharmacology</i> , 2006, 51, 350-357.	2.0	68
151	Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2006, 5, 197-204.	0.8	79
152	A role for hippocampal gastrin-releasing peptide receptors in extinction of aversive memory. <i>NeuroReport</i> , 2006, 17, 935-939.	0.6	23
153	A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2006, 24, 403-412.	1.2	69
154	Gastrin-releasing Peptide Receptor Antagonist Effects on an Animal Model of Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 84-90.	2.5	57
155	Disparities in Cancer Care: A Worldwide Perspective and Roadmap for Change. <i>Journal of Clinical Oncology</i> , 2006, 24, 2135-2136.	0.8	18
156	Cancer Chemotherapy and Cognitive Function in Rodent Models: Memory Impairment Induced by Cyclophosphamide in Mice. <i>Clinical Cancer Research</i> , 2006, 12, 5000-5001.	3.2	72
157	Quantification of the bombesin/gastrin releasing peptide antagonist RC-3095 by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 816, 321-326.	1.2	9
158	Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. <i>Biochemical Pharmacology</i> , 2005, 70, 59-69.	2.0	25
159	Antitumor activity of three benzopyrans isolated from <i>Hypericum polyanthemum</i> . <i>FITOTERAPIA</i> , 2005, 76, 210-215.	1.1	24
160	Screening for antiproliferative activity of six southern Brazilian species of <i>Hypericum</i> . <i>Phytomedicine</i> , 2005, 12, 112-115.	2.3	35
161	Effects of toxic doses of glutamate on Cu/Zn and Mn/superoxide dismutases activities in human glioma cell lines. <i>Journal of Neuro-Oncology</i> , 2005, 71, 9-17.	1.4	4
162	Irinotecan/5-Fluorouracil Combination Induces Alterations in Mitochondrial Membrane Potential and Caspases on Colon Cancer Cell Lines. <i>Oncology Research</i> , 2005, 15, 385-392.	0.6	25

#	ARTICLE	IF	CITATIONS
163	Serum Hsp70 as an Early Predictor of Fatal Outcome after Severe Traumatic Brain Injury in Males. <i>Journal of Neurotrauma</i> , 2005, 22, 966-977.	1.7	59
164	The Irinotecan/5-Fluorouracil Combination Induces Apoptosis and Enhances Manganese Superoxide Dismutase Activity in HT-29 Human Colon Carcinoma Cells. <i>Chemotherapy</i> , 2005, 51, 93-102.	0.8	27
165	MAPK pathway activation in colorectal cancer: a therapeutic opportunity for GRP receptor antagonists. <i>Lancet Oncology</i> , The, 2005, 6, 444-445.	5.1	17
166	Dexamethasone reverses the memory impairment induced by antagonism of hippocampal gastrin-releasing peptide receptors. <i>Peptides</i> , 2005, 26, 821-825.	1.2	22
167	Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095. <i>Peptides</i> , 2005, 26, 2525-2529.	1.2	20
168	Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines. <i>International Journal of Oncology</i> , 2004, 25, 777.	1.4	25
169	Bombesin/gastrin-releasing peptide receptors in the basolateral amygdala regulate memory consolidation. <i>European Journal of Neuroscience</i> , 2004, 19, 1041-1045.	1.2	59
170	RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. <i>European Journal of Pharmacology</i> , 2004, 486, 35-41.	1.7	32
171	Dexamethasone and gastrin-releasing peptide receptors in human lung cells. <i>Lung Cancer</i> , 2004, 46, 129.	0.9	3
172	Neuropeptides and anxiety disorders: bombesin receptors as novel therapeutic targets. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 241-242.	4.0	24
173	The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice. <i>Peptides</i> , 2004, 25, 585-588.	1.2	25
174	Phase II study of thalidomide in patients with metastatic malignant melanoma. <i>Melanoma Research</i> , 2004, 14, 527-531.	0.6	40
175	Asymptomatic Babesiosis in a Child With Hepatoblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 213.	0.3	9
176	Modulation of oxidative stress in response to gamma-radiation in human glioma cell lines. <i>Journal of Neuro-Oncology</i> , 2003, 62, 361-361.	1.4	0
177	Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2003, 21, 359-366.	1.2	19
178	Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. <i>Journal of Neuro-Oncology</i> , 2003, 64, 211-218.	1.4	72
179	Modulation of oxidative stress in response to gamma-radiation in human glioma cell lines. <i>Journal of Neuro-Oncology</i> , 2003, 61, 89-94.	1.4	18
180	Sentinel Lymph Node Procedure in Patients With Epidermoid Carcinoma of the Anal Canal. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 1032-1037.	0.7	31

#	ARTICLE	IF	CITATIONS
181	Overview of Breast Health Care Guidelines for Countries with Limited Resources. <i>Breast Journal</i> , 2003, 9, S42-S50.	0.4	72
182	Treatment of Breast Cancer in Countries with Limited Resources. <i>Breast Journal</i> , 2003, 9, S67-S74.	0.4	58
183	Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. <i>Cancer Letters</i> , 2003, 198, 211-218.	3.2	95
184	Intrahippocampal infusion of the bombesin/gastrin-releasing peptide antagonist RC-3095 impairs inhibitory avoidance retention. <i>Peptides</i> , 2003, 24, 1069-1074.	1.2	45
185	Marine-derived anticancer agents in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1367-1383.	1.9	82
186	Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer. <i>International Journal of STD and AIDS</i> , 2003, 14, 258-265.	0.5	24
187	High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Rescue in a Patient With Pleuropulmonary Blastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 78-81.	0.3	17
188	Marine-derived anticancer agents in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1367-1383.	1.9	6
189	Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas?. <i>Oncologist</i> , 2002, 7, 17-33.	1.9	141
190	Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 496-501.	0.6	81
191	Anti-tumour Screening of Brazilian Plants. <i>Pharmaceutical Biology</i> , 2002, 40, 603-616.	1.3	26
192	In vitro Cytotoxicity of Extracts from Brazilian Asteraceae. <i>Pharmaceutical Biology</i> , 2002, 40, 494-500.	1.3	20
193	Comparative genotoxic effect of vincristine, vinblastine, and vinorelbine in somatic cells of <i>Drosophila melanogaster</i> . <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2002, 519, 141-149.	0.9	32
194	Detecção do linfonodo sentinela em câncer da mama: comparação entre métodos. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2002, 24, 479-484.	0.3	1
195	Anticancer, antichemotactic and antimicrobial activities of marine sponges collected off the coast of Santa Catarina, southern Brazil. <i>Journal of Experimental Marine Biology and Ecology</i> , 2002, 281, 1-12.	0.7	63
196	Von Willebrand factor in colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2002, 17, 42-45.	1.0	34
197	Metastatic renal cell carcinoma involving the rectum. <i>International Journal of Colorectal Disease</i> , 2002, 17, 359-361.	1.0	15
198	Marine organisms as a source of new anticancer agents. <i>Lancet Oncology</i> , The, 2001, 2, 221-225.	5.1	200

#	ARTICLE	IF	CITATIONS
199	Malignant disease and von Willebrand factor. <i>Lancet Oncology</i> , The, 2001, 2, 716-717.	5.1	5
200	Natural products in anticancer therapy. <i>Current Opinion in Pharmacology</i> , 2001, 1, 364-369.	1.7	477
201	Fractionated Doses of Oral Etoposide in the Treatment of Patients With AIDS-Related Kaposi Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 177-184.	0.6	16
202	Sentinel lymph node identification and sampling in women with early breast cancer using 99mTc labelled dextran 500 and patent blue V dye. <i>Nuclear Medicine Communications</i> , 2001, 22, 1109-1117.	0.5	15
203	Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma. <i>Annals of Oncology</i> , 2001, 12, 1757-1759.	0.6	24
204	Anticancer drugs from nature. <i>Medical and Pediatric Oncology</i> , 2001, 37, 79-80.	1.0	0
205	Multidrug resistance gene expression during the murine ontogeny. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 255-270.	2.2	20
206	Cervical Cancer Screening in Porto Alegre, Brazil: Alternative Methods for Detecting Cancer Precursors in a Developing Country. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 24-28.	0.9	5
207	A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. <i>Investigational New Drugs</i> , 2000, 18, 83-91.	1.2	103
208	Cellular and Clinical Pharmacokinetic/Pharmacodynamic Basis for Lack of Efficacy of 21-Day Continuous Topotecan in Patients with Untreated Advanced Adenocarcinoma of the Pancreas. <i>Tumori</i> , 2000, 86, 458-464.	0.6	1
209	Protein Kinase C-Mediated in vitro Invasion of Human Glioma Cells through Extracellular-Signal-Regulated Kinase and Ornithine Decarboxylase. <i>Pathobiology</i> , 2000, 68, 113-123.	1.9	19
210	Marine organisms and other novel natural sources of new cancer drugs. <i>Annals of Oncology</i> , 2000, 11, 235-244.	0.6	51
211	Anti-Cancer Drug Discovery and Development in Brazil: Targeted Plant Collection as a Rational Strategy to Acquire Candidate Anti-Cancer Compounds. <i>Oncologist</i> , 2000, 5, 185-198.	1.9	175
212	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 235-244.	0.6	31
213	Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to $^{137}\text{Cs}$ -radiation and BCNU. <i>European Journal of Cancer</i> , 1999, 35, 833-839.	1.3	22
214	Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. <i>European Journal of Cancer</i> , 1999, 35, 1851-1861.	1.3	86
215	Phenotype modulation of cellular UV-sensitivity. <i>Cancer Letters</i> , 1999, 145, 65-72.	3.2	7
216	Essential drugs for cancer therapy: A World Health Organization consultation. <i>Annals of Oncology</i> , 1999, 10, 385-390.	0.6	79

#	ARTICLE	IF	CITATIONS
217	Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 45, 47-53.	1.1	11
218	Phase II Study of Pentosan Polysulfate (PPS) in Patients with AIDS-related Kaposi's Sarcoma. <i>Tumori</i> , 1996, 82, 360-363.	0.6	29
219	Cancer research campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials. <i>European Journal of Cancer</i> , 1993, 29, 1907-1910.	1.3	14
220	Anticancer drug screening and discovery in the 1990s: a European perspective. <i>European Journal of Cancer</i> , 1993, 29, 3-14.	1.3	33
221	EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. <i>European Journal of Cancer</i> , 1993, 29, 897-906.	1.3	112
222	Reversal by Interleukin-2 of Alopecia Universalis, Mucocutaneous Candidiasis, and Sexual Impotence in a Patient With Malignant Thymoma. <i>Journal of the National Cancer Institute</i> , 1993, 85, 673-673.	3.0	16
223	Laboratory and phase I studies of new cancer drugs. <i>Current Opinion in Oncology</i> , 1992, 4, 1065-1072.	1.1	4
224	Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts. <i>European Journal of Cancer</i> , 1992, 28, 767-773.	1.3	18
225	A study of the delivery-targeting concept applied to antineoplastic drugs active on human osteosarcoma. I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues. <i>European Journal of Medicinal Chemistry</i> , 1992, 27, 825-833.	2.6	32
226	Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1637-1639.	0.9	24
227	EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agents. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1162-1168.	0.9	27
228	Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 25, 345-351.	1.1	40
229	Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 1675-1681.	0.9	14
230	A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2. <i>Cancer Treatment Reviews</i> , 1989, 16, 105-109.	3.4	11
231	DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effects. <i>Biochemical Pharmacology</i> , 1988, 37, 3257-3266.	2.0	32
232	The main steps in the development of anticancer agents. <i>Radiotherapy and Oncology</i> , 1988, 12, 301-313.	0.3	28
233	Pharmacokinetics of brequinar sodium (NSC 368390; DUP 785) in cerebrospinal fluid. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 1903-1904.	0.9	4
234	Double-minute chromatin bodies in HL-60 leukemia cells sensitive and resistant to differentiation inducing agents. <i>Cell Biology International Reports</i> , 1987, 11, 651-655.	0.7	5

#	ARTICLE	IF	CITATIONS
235	Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 739-743.	0.9	9
236	Clinical trials in advanced breast cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 595-597.	0.9	5
237	Growth inhibitory effects of 5-aza-2â€²-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction. <i>Biochemical and Biophysical Research Communications</i> , 1986, 141, 629-635.	1.0	15